Delcath Systems, Inc. (DCTH)

NASDAQ: DCTH · IEX Real-Time Price · USD
4.56
0.06 (1.33%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap36.05M
Revenue (ttm)3.54M
Net Income (ttm)-27.11M
Shares Out7.91M
EPS (ttm)-3.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,521
Open4.61
Previous Close4.50
Day's Range4.40 - 4.78
52-Week Range4.30 - 13.50
Beta0.55
AnalystsBuy
Price Target22.44 (+392.1%)
Earnings DateMay 10, 2022

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rat...

IndustryMedical Devices
Founded1988
CEOJennifer Simpson
Employees55
Stock ExchangeNASDAQ
Ticker SymbolDCTH
Full Company Profile

Financial Performance

In 2021, DCTH's revenue was $3.56 million, an increase of 115.98% compared to the previous year's $1.65 million. Losses were -$25.65 million, 6.18% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is 22.44, which is an increase of 392.11% from the latest price.

Price Target
$22.44
(392.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -19.05% and 70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today report...

2 weeks ago - GlobeNewsWire

Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

2 weeks ago - GlobeNewsWire

Delcath Systems to Host First Quarter 2022 Results

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...

4 weeks ago - GlobeNewsWire

Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will partic...

1 month ago - GlobeNewsWire

Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...

1 month ago - GlobeNewsWire

Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today repor...

2 months ago - GlobeNewsWire

Delcath Systems to Host Fourth Quarter and Full Year 2021 Results

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...

2 months ago - GlobeNewsWire

Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased ...

2 months ago - GlobeNewsWire

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...

3 months ago - GlobeNewsWire

Delcath Systems to Present at Upcoming Virtual Investor Conferences

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...

3 months ago - GlobeNewsWire

Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...

3 months ago - GlobeNewsWire

Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

Delcath Systems Inc's  DCTH single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Rese...

3 months ago - Benzinga

Results of Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Melanoma Research

Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of 66.7%...

3 months ago - GlobeNewsWire

David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary

NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ...

4 months ago - GlobeNewsWire

Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...

4 months ago - GlobeNewsWire

Delcath Systems Reveals Initial Survival Data From Ocular Melanoma Trial

Delcath Systems Inc (NASDAQ: DCTH) has announced results from the Phase 3 FOCUS study of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metas...

5 months ago - Benzinga

Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Misses Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -3.30% and -9.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Recap: Delcath Systems Q3 Earnings

Delcath Systems (NASDAQ:DCTH) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Delcath Systems Announces Third Quarter 2021 Results

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today r...

6 months ago - GlobeNewsWire

Delcath Systems, Inc. (DCTH) Stock Jumps 6.6%: Will It Continue to Soar?

Delcath Systems, Inc. (DCTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

6 months ago - Zacks Investment Research

Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on N...

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announ...

6 months ago - GlobeNewsWire

Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...

6 months ago - GlobeNewsWire

Will Delcath Systems, Inc. (DCTH) Report Negative Earnings Next Week? What You Should Know

Delcath Systems, Inc. (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research